Nebenwirkungen · Pemazyre
Pemazyre 4.5 mg tablets Pemazyre 9 mg tablets Pemazyre 13.5 mg tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-145621 · Präparat HOS-099381
Hyperphosphataemia Hyperphosphataemia was reported in 60.5 % of all patients treated with pemigatinib. Hyperphosphataemia above 7 mg/dL and 10 mg/dL was experienced by 27.2 % and 0.7 % of patients, respectively. Hyperphosphataemia usually develops within the first 15 days. None of the reactions were ≥ Grade 3 in severity, serious or led to discontinuation of pemigatinib. Dose interruption occurred in 1.4 % patients and reduction in 0.7 % of patients. These results suggest that dietary phosphate restriction and/or administration of phosphate-lowering therapy along with the 1-week dose holiday were effective strategies for managing this on-target effect of pemigatinib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T16:40:00Z · SHA-256 8e535a113ae402c5cf3666356fff94af919f2d5254b892ef44d65c6c6506d36b · Passage dcc8fa63c1510a1cf2fce0d3df668e0e123b7a4e034932de908c001df58c5a14 · Zeichen 3635–4310 im Abschnitt